About Us > Robert Somer, MD

Robert Somer, MD

Highlights

  • Head of the genitourinary malignancy program and the associate director of the breast cancer program at the MD Anderson Cancer Center at Cooper
  • Director of the clinical trials office at the cancer center
  • Associate professor of medicine and chair of the admissions committee at the Cooper Medical School of Rowan University
featured_paragraph

Robert A. Somer, MD, is the head of the genitourinary malignancy program and the associate director of the breast cancer program at the MD Anderson Cancer Center at Cooper, in Voorhees, New Jersey. He is also the director of the clinical trials office at the cancer center, and is an associate professor of medicine and chair of the admissions committee at the Cooper Medical School of Rowan University.

general_content

In addition to being instrumental in establishing a state-of-the-art, comprehensive research program, Dr. Somer has received many awards during his career, and sits on many advisory boards for cancer research. He has been invited to give local, national and international presentations, and has co-authored many publications and abstracts ranging from basic science research to clinical research and cancer treatment.

 

contributions_carousel

Contributions

Medicare Will Cover FDA-Approved Genomic Tests

05/30/18 | BY: Erin Rowley

The Centers for Medicare & Medicaid Services announced it would cover FDA-approved next-generation sequencing tests in people with certain advanced cancers, including metastatic breast cancer. The results of these tests can sometimes be used to make treatment decisions.

Read More
 | 8 Min. Read

Everolimus gains FDA approval for metastatic breast cancer

08/01/12 | BY: Robert Somer

Postmenopausal women with metastatic, hormone receptor-positive breast cancer may now be treated with everolimus (Afinitor) in combination with exemestane (Aromasin), following FDA’s recent approval of the tablet medicine.

Read More
 | 5 Min. Read